Skip to content
TrialScanner

NCT07303907

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

Phase 2CompletedDFTXLead

Registry record

Lead sponsor
Definium Therapeutics US, Inc.
Conditions
Autism Spectrum Disorder; ASD
Primary completion
Sep 16, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07303907 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

3 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.